Skip to content
Evigrade
CriticalAntidepressants. Other antidepressants of herbal origin×Second-generation systemic triazole antifungal

Updated · Methodology

Mechanism

The liver enzymes CYP3A4 and CYP3A5 take part in isavuconazole metabolism, so medicines that induce these enzymes can lower its blood levels (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). The isavuconazole SmPC classes St John's wort as a strong inducer of these enzymes: the combination has not been studied, but isavuconazole levels may fall significantly (isavuconazole SmPC, EMA, section 4.5; isavuconazole label, US Food and Drug Administration, FDA, section 4). Hyperforin in St John's wort induces CYP3A4, CYP2B6, CYP2C9, CYP2C19 and the transporter P-glycoprotein in a dose-dependent way (St John's wort herbal monograph, EMA, sections 4.5 and 5.2). According to the Spanish St John's wort SmPC, medicines metabolised through CYP3A4 may then reach lower levels and have a reduced therapeutic effect (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, EMA, section 4.5).

Symptoms

The combination itself usually causes no symptoms: isavuconazole blood levels may fall significantly (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5), and its therapeutic effect may be reduced (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Isavuconazole is used for invasive aspergillosis and for mucormycosis when amphotericin B is not appropriate (isavuconazole SmPC, EMA, section 4.1). A weaker antifungal effect shows only as an infection that responds less well to treatment.

Management

The combination is contraindicated: St John's wort is on the list of strong CYP3A4/5 inducers that must not be given with isavuconazole (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.3 and 4.5; isavuconazole label, US Food and Drug Administration, FDA, sections 4 and 5.5). The contraindication does not depend on the St John's wort dose. The EMA herbal monograph does not name isavuconazole. It calls for special care with all medicines whose metabolism depends on CYP3A4. For traditional use products with a daily hyperforin intake of up to 1 mg, taken for no longer than 2 weeks, it reports no clinically relevant interactions (St John's wort herbal monograph, EMA, section 4.5). This exception does not change the contraindication in the isavuconazole documents. The Spanish St John's wort SmPC does not name isavuconazole either (St John's wort SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). The authorisation of that product has been suspended since 11 June 2026. The isavuconazole documents do not say how long to wait between the last dose of St John's wort and the start of isavuconazole. According to the monograph, increased enzyme activity returns to normal within 1 week of stopping St John's wort (St John's wort herbal monograph, EMA, section 4.5).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Hypericum perforatum

Other interactions with Isavuconazole